Quantification of HIV-1 RNA levels is a vital tool in the medical management of individuals infected with HIV. The commercially available US Federal Drug Administration (FDA)-approved assays vary in their ability to accurately measure and detect significant changes in plasma viral load. A more precise assay can accurately distinguish true clinically significant biologic changes in viral plasma load from background noise, or systematic variation. These differences in precision between assays are profound at low, near-cutoff levels, but also occur throughout the dynamic range of the assays. This review examines the precision specifications, expressed as fold changes in test and retesting, across the dynamic ranges of the Bayer Versant bDNA assay, and the two available versions of the Roche Amplicor Monitor PCR assays. Highly validated data from their respective package inserts are analyzed to confirm each assay's performance throughout its dynamic range. The precision of a viral load assay is critical to patient management, and gives the clinician a clearer picture of the patient's true virologic status that is attributable to infection or treatment as opposed to systematic variation in assays. ;1(4):134-140. © 2002 IAPAC. 
Introduction
Since the mid-1990s, quantitative HIV-1 RNA testing in plasma has become the standard of care in predicting progression of HIV disease, and for the therapeutic monitoring of individuals on antiretroviral drug treatment regimens. The early comprehensive Multicenter AIDS Cohort Study (MACS) described the clinical association of baseline viral load and the rate of disease progression, independent of peripheral blood CD4 T-lymphocyte count, allowing a prognostic correlation between viral load values and clinical disease. [1] [2] [3] With the introduction of an arsenal of anti-HIV therapies, viral load testing was quickly adopted in clinical practice to monitor patient response to these regimens. 4, 5 The first commercially available viral load assays were capable of measuring at their lower limits of detection from 400 to 500 copies/mL. An evolving understanding of HIV disease and treatments, coupled with increasing therapeutic options, saw the advent of increasingly more sensitive HIV viral load assays. These assays are generally capable of measuring levels below 100 copies/mL. Even these extremes of plasma viremia have been shown to predict "virologic success" of therapies. This paper compares the precision of two commonly utilized viral load assays, and explores the impact that assay precision has on HIV patient management.
Guidelines for use of viral load tests
According to the current guidelines for the treatment of patients with HIV-1 infection from the US Department of Health and Human Services (DHHS), the objective of antiretroviral therapy is maximal suppression of viral replication to levels below the limit of detection by a sensitive viral load assay. 6 The recommendation to use more sensitive versions of viral load assays is driven by evidence that increased levels of viral suppression lead to better treatment outcomes. In a clinical trial using a research assay, suppression of plasma HIV RNA levels below 20 copies/mL was associated with a longer response to antiretroviral therapy, compared with that achieved when viral suppression was below 500 copies/mL. 7 The evidence that viral replication persists in patients with undetectable viral load has also prompted interest in the ability of an HIV RNA assay to measure very low viral load levels. 8 It is currently unknown whether a true, clinically relevant difference exists between suppression of viral load below 100 copies/mL versus 50 copies/mL. However, increasing attention is being paid to the meaning of very low, but detectable viral loads, at or near the cutoff of commercial viral load assays.
Definition of sensitivity, precision, and dynamic range
Sensitivity: There are currently four FDA-approved assays for measuring HIV-1 viral load: Bayer VERSANT ® HIV-1 RNA 3.0 Assay (bDNA), the Roche Amplicor ® HIV-1 MONITOR ® Test versions 1.0 and 1.5 (PCR), and the bioMérieux NucliSens™ HIV-1 QT Test. According to package inserts, the sensitivity claim of the Bayer bDNA is 75 copies/mL, the Roche PCR assay is 50 copies/mL, and the bioMérieux NASBA assay is 176 copies/mL. The assay sensitivity is defined as the lowest viral load level that can be detected 95 percent of the time. This statistical method of assessing sensitivity is generally considered to be the standard to determine the lower quantitative "limit of detection" (LoD) for quantitative HIV RNA assays.
Prior to FDA approval, the bDNA assay had a cutoff of 50 copies/mL based on the point at which 95 percent of HIV RNA negative samples would produce a belowcutoff result. The current, FDA-approved bDNA assay now utilizes the industry-wide standard based on 95 percent detection of samples at the assay cutoff (LoD). From clinical trial studies this was demonstrated to be 75 copies/mL. 9 
Accuracy
Refers to the ability of the assay to Results from clinical trial with one determine the true value of an analyte. assay can be applied in management Very difficult to establish "gold" standard of patients with any of the assays. for viral load (VL). Calibration of assays Treatment (International AIDS Society and to common standard should result in DHHS) guidelines describe a viral load consistency of quantification between threshold for initiation of therapy. assays.
Standardization will result in common management thresholds across all assays.
Precision
Capacity to achieve very similar viral Physician and patient need to understand (reproducibility) quantification values regardless of the if viral load decreases or increases are laboratory, day, operator, instrument significant, or within the variability expected or kit lot. Determines the change in from biological variation plus systematic viral load that is statistically significant.
(assay) variation. Treatment guidelines describe viral load changes of 3-fold (or 0.5 log 10 ) as the minimum change that is considered significant.
Specificity
High specificity means that HIV-HIV viral load assays designed to be used negative samples will not be positive only in individuals who are known to in a viral load test for HIV.
be HIV-positive (eg, antibody-positive). High specificity gives physicians and patients confidence that the assay is really only assessing HIV RNA.
Linearity
Refers to the degree to which the Important to know that changes in viral load assay standard curve approximates reflect actual changes in amount of virus a straight line. Used to determine (without contributions from quantification the linear range of the assay.
biases in specific areas of the dynamic Linearity is a measure of how accurately range). the assay measures changes in viral load throughout its dynamic range.
Equal quantification Capacity of assay to accurately
Since treatment guidelines depend on of all genotypes measure viral load regardless of specific viral loads, then assay must sequence variation in HIV RNA.
accurately quantify virus regardless of HIV group or subtype. Assays that under-quantify certain subtypes have yielded viral loads that are inconsistent with CD4 counts and/or the clinical status of the patient.
Clinically, the goal of therapy is to suppress viral load to below the LoD. It is yet to be determined if the differences in LoDs between commercial assays would result in different treatment practices, or patient outcomes.
Precision:
The precision or reproducibility of an assay is defined by its ability to obtain the same answer when tested repeatedly. Traditionally, manufacturers of viral load assays measure precision by the ability of the assay to detect "fold changes," or the ability to detect a significant change from one measurement to the next. The statistical methods used to calculate and report precision claims have not been standardized in the industry. For example, Roche defines fold change for its polymerase chain reaction (PCR) assay as the expected variation calculated from multiple determinations of a single measurement. Another statistically relevant method of assessing fold change uses sequential time point analysis that reflects the use of viral load assays in clinical practice. 10 The bDNA assay utilizes this method. Bayer defines fold change as the expected variation between two independent measurements.
The DHHS guidelines state: "A minimally significant change in plasma viremia is considered to be a 3-fold or 0.5 log 10 increase or decrease…In general, viral loads and trends in viral load are felt to be more informative for guiding decisions regarding antiretroviral therapy than are CD4 + T cell counts."
The concept of a fold change refers to two serial measurements taken at different points in time, or trends in viral load. The formula used by the bDNA assay for calculating fold changes is appropriate because it considers the variation between two measurements from different time points.
Dynamic range: The dynamic range of an assay is defined as the quantitative range over which the assay can reliably report results. Since viral levels are obtained at varying time points during treatment regimens, it is essential that the assay be able to accurately follow changes in HIV RNA across the wide range of clinically expected values. The bDNA methodology utilizes a single assay to span the entire dynamic range of 75 to 500,000 copies/mL. By comparison, the PCR methodology uses two separate assays: an ultrasensitive version that has a dynamic range of 50 to 75,000 copies/mL, and a standard version that has an overlapping dynamic range of 400 to 750,000 copies/mL. Table 1 describes the performance characteristics and their corresponding clinical significance for HIV viral load assays. The overall reliability of an HIV RNA viral Similarly, a precise (reproducible) assay should identify changes in viral load that are biologically and statistically significant (3-fold) . Finally, the assay should remain reproducible across a wide dynamic and clinically relevant reporting range. Therefore, an "ideal" viral load assay would have good sensitivity while being able to maintain excellent precision throughout a wide dynamic range. These specifications are critical performance characteristics of an HIV RNA assay, and should be considered by clinicians when choosing a viral load assay.
An "ideal" quantitative HIV RNA assay

A critical look at precision and fold changes
The DHHS guidelines state that in order for an HIV RNA assay to reliably and reproducibly assess clinically significant changes in viral load, the assay must be able to distinguish a 3-fold (or 0.5 log 10 ) change in viral load from the assay's inherent or background variability. 6 Table 2 compares the reproducibility of the Bayer bDNA version 3.0 (bDNA 3.0) and the Roche PCR version 1.0 (PCR 1.0) assays at values near their cutoffs, as performed in approved labs, according to the package insert.
The data show the fold change performance for the two assays in question, using a statistical method that does not take into account serial measurements. The data illustrate that the fold change at each viral concentration listed, using the bDNA 3.0 assay, is less than three. The fold change value at the 50 copies/mL 15 Procedure (data from Roche package insert) 16 Approximate copy level 620 c/mL 6,203 c/mL 62,028 c/mL 620,282 c/mL 500 c/mL >1000 c/mL level utilizing the PCR 1.0 assay is 4.8. This represents a range of values between 10 and 240 copies/mL, shown in Figure 1 .
.0 Amplicor HIV Monitor Test (version 1.0) clinical trial data generated at PCR, Standard Specimen Processing five independent laboratories
Typically, patients on antiretroviral therapy are tested every three to four months to monitor their viral load levels. This sequential monitoring of viral load is an essential tool for assessing therapy success or failure because significant changes in viral load can predict changes in treatment efficacy and clinical status of the patient. Additional variability is introduced when looking at sequential or serial HIV RNA measurements. Table 3 compares the fold change specification of the same two HIV RNA assays, using a statistical method of calculating fold change that takes into account the additional biological variability associated with serial viral load measurements.
When the effect of serial determination of viral load measurement is taken into account, the data show that the bDNA 3.0 assay is able to reproducibly detect 3-fold changes at 75 copies/mL. By comparison, the PCR 1.0 assay's precision at 75 copies/mL is 4.2-fold. At the sensitivity claim of 50 copies/mL, the PCR 1.0 assay precision is 9.3-fold. This represents a range of values between 5 and 460 copies/mL, shown in Figure 2 . Table 4 compares the precision of the bDNA 3.0 assay and the PCR 1.0 assay (Standard Procedure) at concentrations greater than 500 copies/mL.
The data indicate that the bDNA 3.0 assay maintains good precision for levels above 500 copies/mL and meets the DHHS guidelines for ability to detect 3-fold changes in viral load. Conversely, the Standard Procedure PCR 1.0 assay has fold changes that exceed three for both concentrations that are reported in their package insert.
A newer version of the Roche HIV assay (Amplicor HIV-1 Monitor Test, version 1.5) has recently been approved. According to the package insert for the 1.5 assay, When Coefficients of Variation (CVs) are converted to fold changes for the Roche PCR version 1.5 (PCR 1.5) assay, using the method of calculating fold change that takes into account serial viral load measurements, the data in Table 4 can be derived.
Package insert data demonstrate that the new PCR 1.5 assay is able to detect 3-fold changes only in the range of 2,000 to 100,000 copies/mL for the standard specimen preparation procedure and 400 to 1,000 copies/mL for the ultrasensitive specimen preparation procedure.
Peer-reviewed publications evaluate comparative performance of bDNA and PCR
Several studies published in peer-reviewed journals have evaluated the performance characteristics of the bDNA 3.0 and PCR 1.0 assays. A multicenter study in Canada and the United States showed that the bDNA 3.0 assay displayed a higher level of precision than the PCR 1.0 or Biomérieux assays. 19 Likewise, the multilaboratory study, conducted with the AIDS Clinical Trials Group (ACTG), stated that both the bDNA 3.0 assay and PCR 1.0 ultrasensitive have "comparable low levels of HIV-1 RNA... for the assessment of viral suppression in clinical trials and in clinical practice." The authors of the study also stated that the bDNA 3.0 assay has "excellent reproducibility, a broad linear range and a good sensitivity for the quantitation of HIV-1 RNA in plasma down to 100 copies/mL." They indicated that the within run standard deviation (SD) for the PCR 1.0 assay was "higher than the SD for the bDNA assay at all concentrations." (Note: ACTG uses a method other than LoD to determine assay sensitivity). 20 Similarly, a new paper stated that bDNA 3.0 was more reliable and accurate than PCR 1.5, in studies that compared multiple serially diluted viral isolates of HIV-1 Group M, subtypes A through F. Accuracy analysis showed that the "data points more closely distributed about their respective regression lines." According to the authors, bDNA 3.0 demonstrated greater reliability than PCR 1.5. 21
The impact of assay performance in managing HIV patients in clinical practice
The precision of a viral load assay is significant for the HIV-treating clinician who relies on the accuracy of the HIV RNA levels, and on the reproducibility of the measurements. If an assay is unable to distinguish 3-fold changes across its full dynamic range, the laboratory findings may not correlate with the patient's clinical presentation. Increases or decreases in serial measurements of HIV RNA could be due to assay variation or poor precision, rather than actual changing virologic response to treatment. The issue is further complicated by the occurrence of transient viremia or "viral blips" that can be seen in HIV RNA levels. Recent studies considered the significance of transient viremia and viral rebound, [22] [23] [24] and showed that viral blips are probably not clinically significant because they did not predict disease progression or subsequent treatment failure. These studies illustrate the importance of being able to distinguish between true viral rebound and what is most likely a transient viral blip, whether these may be due to varying treatment adherence, virologic breakthrough, or systematic assay variation.
As more research studies look at the significance of viral kinetics, it is important to use a precise assay so that the rise and decline in viral load can accurately be categorized as true biologic variation versus an artifact of systematic assay variation. 25 If an assay is unable to distinguish clinically significant changes due to poor precision, it is less likely to give accurate answers for HIV RNA values. As described in Table 1 , knowledge that viral load changes are statistically and clinically significant offers a better assessment of therapeutic success or failure and greater confidence in treatment decisions.
Discussion
Studies are in progress to assess the clinical relevance of plasma HIV RNA levels that approach the limits of detection for available viral load assays. The results of these studies should provide additional evidence supporting the need for accurate and precise viral load determinations below 100 copies/mL. For the present, sensitivity, or the ability to measure as low as possible, is not the only specification that contributes to the strength of a commercial HIV RNA assay. Perhaps a more important clinical characteristic of an HIV RNA assay is the ability to reproducibly measure HIV RNA levels across its entire dynamic range. Inherent in this performance characteristic is an assay's ability to accurately measure and appropriately characterize fold changes from one viral load measurement to the next, thereby demonstrating virologic response to therapy as opposed to assay variation. ■
